In fairness, MAXY stands to reap another $65-123M give or take million for the pharmaceutical application of the technology if Astellas buys out the Perseid joint venture that holds the molecular breeding license for therapeutics
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.